Linda Pudelko1, Steven Edwards2, Mirela Balan3, Daniel Nyqvist3, Jonathan Al-Saadi1, Johannes Dittmer1, Ingrid Almlöf1, Thomas Helleday1, Lars Bräutigam1. 1. Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden. 2. Department of Applied Physics, Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden. 3. Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Abstract
Background: Glioblastoma (GBM) is an aggressive form of brain cancer with poor prognosis. Although murine animal models have given valuable insights into the GBM disease biology, they cannot be used in high-throughput screens to identify and profile novel therapies. The only vertebrate model suitable for large-scale screens, the zebrafish, has proven to faithfully recapitulate biology and pathology of human malignancies, and clinically relevant orthotopic zebrafish models have been developed. However, currently available GBM orthotopic zebrafish models do not support high-throughput drug discovery screens. Methods: We transplanted both GBM cell lines as well as patient-derived material into zebrafish blastulas. We followed the behavior of the transplants with time-lapse microscopy and real-time in vivo light-sheet microscopy. Results: We found that GBM material transplanted into zebrafish blastomeres robustly migrated into the developing nervous system, establishing an orthotopic intracranial tumor already 24 hours after transplantation. Detailed analysis revealed that our model faithfully recapitulates the human disease. Conclusion: We have developed a robust, fast, and automatable transplantation assay to establish orthotopic GBM tumors in zebrafish. In contrast to currently available orthotopic zebrafish models, our approach does not require technically challenging intracranial transplantation of single embryos. Our improved zebrafish model enables transplantation of thousands of embryos per hour, thus providing an orthotopic vertebrate GBM model for direct application in drug discovery screens.
Background: Glioblastoma (GBM) is an aggressive form of brain cancer with poor prognosis. Although murine animal models have given valuable insights into the GBM disease biology, they cannot be used in high-throughput screens to identify and profile novel therapies. The only vertebrate model suitable for large-scale screens, the zebrafish, has proven to faithfully recapitulate biology and pathology of humanmalignancies, and clinically relevant orthotopic zebrafish models have been developed. However, currently available GBM orthotopic zebrafish models do not support high-throughput drug discovery screens. Methods: We transplanted both GBM cell lines as well as patient-derived material into zebrafish blastulas. We followed the behavior of the transplants with time-lapse microscopy and real-time in vivo light-sheet microscopy. Results: We found that GBM material transplanted into zebrafish blastomeres robustly migrated into the developing nervous system, establishing an orthotopic intracranial tumor already 24 hours after transplantation. Detailed analysis revealed that our model faithfully recapitulates the human disease. Conclusion: We have developed a robust, fast, and automatable transplantation assay to establish orthotopic GBM tumors in zebrafish. In contrast to currently available orthotopic zebrafish models, our approach does not require technically challenging intracranial transplantation of single embryos. Our improved zebrafish model enables transplantation of thousands of embryos per hour, thus providing an orthotopic vertebrate GBM model for direct application in drug discovery screens.
Authors: E Rampazzo; L Persano; F Pistollato; E Moro; C Frasson; P Porazzi; A Della Puppa; S Bresolin; G Battilana; S Indraccolo; G Te Kronnie; F Argenton; N Tiso; G Basso Journal: Cell Death Dis Date: 2013-02-21 Impact factor: 8.469
Authors: C J Eden; B Ju; M Murugesan; T N Phoenix; B Nimmervoll; Y Tong; D W Ellison; D Finkelstein; K Wright; N Boulos; J Dapper; R Thiruvenkatam; C A Lessman; M R Taylor; R J Gilbertson Journal: Oncogene Date: 2014-04-21 Impact factor: 9.867
Authors: Binwu Tang; Asaf Raviv; Dominic Esposito; Kathleen C Flanders; Catherine Daniel; Bao Tram Nghiem; Susan Garfield; Langston Lim; Poonam Mannan; Ana I Robles; William I Smith; Joshua Zimmerberg; Rea Ravin; Lalage M Wakefield Journal: Stem Cell Reports Date: 2014-12-11 Impact factor: 7.765
Authors: Hayley P Ellis; Mark Greenslade; Ben Powell; Inmaculada Spiteri; Andrea Sottoriva; Kathreena M Kurian Journal: Front Oncol Date: 2015-11-16 Impact factor: 6.244
Authors: Uswa Shahzad; Michael S Taccone; Sachin A Kumar; Hidehiro Okura; Stacey Krumholtz; Joji Ishida; Coco Mine; Kyle Gouveia; Julia Edgar; Christian Smith; Madeline Hayes; Xi Huang; W Brent Derry; Michael D Taylor; James T Rutka Journal: Neuro Oncol Date: 2021-05-05 Impact factor: 12.300
Authors: Faye L Robertson; Maria-Angeles Marqués-Torrejón; Gillian M Morrison; Steven M Pollard Journal: Dis Model Mech Date: 2019-09-06 Impact factor: 5.758